Acrivon Therapeutics, Inc. · NASDAQ:ACRV
Acrivon Therapeutics — TD Cowen Healthcare Conference 2026
9 slides from Acrivon Therapeutics's conference presentation, Mar 2, 2026
Slide 1: TD Cowen Healthcare Conference: Acrivon Therapeutics Fireside Chat
Acrivon Therapeutics TD COWEN HEALTHCARE CONFERENCE Acrivon Therapeutics Fireside Chat Boston, MA March 2, 2026
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and plans and objectives o
Slide 3: Expert KOL Panel Discussing ACR-368 Data in Serous Endometrial Cancer at ESGO
EXPERT KOL PANEL DISCUSSING ACRIVON’S ACR-368 DATA IN SEROUS ENDOMETRIAL CANCER AT ESGO CONGRESS FEB 27, 2026 Robert Coleman, Ramez Eskander, Domenica Lorusso, Brian Slomovitz, Peter Blume-Jensen, Mansoor Raza Mirza, M.D. M.D. M.D., Ph.D. M.D. M.D., Ph.D. M.D. GOG Partners, Special Julie St. John En
Slide 4: Serous Endometrial Cancer - A Significant Unmet Need
SEROUS ENDOMETRIAL CANCER - A SIGNIFICANT UNMET NEED EC Mortality EC Prevalence (US + EU) = ~44K1, 3 ~2.4M patients1, 3 Disproportionate Mortality ~58,800 • Accounts for ~40-50% of all endometrial cancer deaths.5 serous EC4 Serous EC Limited Effective Treatment Options Mortality 40-50% • Only modera
Slide 5: Better ORR Observed in Subjects with ≤2 Prior Lines of Therapy
BETTER ORR OBSERVED IN SUBJECTS WITH ≤2 PRIOR LINES OF THERAPY Arm 1 (BM+) ARM 2 (BM-) ACR-368 ACR-368 + ULDG ORR = 44% ORR = 26% BOR by RECIST 1.1 (95% CI, 27 - 63) (95% CI, 14 - 42) on study treatment* # # # n = 25 n = 35 * Best of BICR and/or PI # Unconfirmed PR Non QC’ed data based on EDC data e
Slide 6: Significant ORR in Serous All-Comer Population with ≤2 Prior Lines of Therapy
SIGNIFICANT ORR IN SEROUS ALL-COMER POPULATION WITH ≤ 2 PRIOR LINES OF THERAPY Serous (≤ 2 Prior Lines) Non-Serous (≤ 2 Prior Lines) ORR = 52% ORR = 22% (95% CI, 33 - 71) (95% CI, 11 - 37) BOR by RECIST 1.1 on study treatment* # # # n = 23 n = 37 DCR: 74%, CBR (16 weeks): 65% * Best of BICR and/or P
Slide 7: Favorable Safety Profile
FAVORABLE SAFETY PROFILE Treatment-Related Adverse Arm 1 Arm 2 Events (ACR-368) (ACR-368 + N=40 ULDG) N = number of subjects (%) Grades 3/4 N=48 • Limited, transient, mechanism- Grades 3/4 based hematological AEs Thrombocytopenia 9 (22) 17 (34) • Notable Absence of Anemia 11 (27) 22 (46) - GI toxici
Slide 8: Rapid US+EU Enrollment of Serous EC Cohort Provides Additional Registrational Intent Opportunity
RAPID US+EU ENROLLMENT OF SEROUS EC COHORT PROVIDES ADDITIONAL REGISTRATIONAL INTENT OPPORTUNITY • Serous EC shows particularly Subjects relapsed after prior platinum- based chemotherapy high ORR in both BM+ and BM- and one prior line of anti-PD-(L)1 therapy tumors • ACR-368 has a favorable safety B
Slide 9: ACR-2316 Clinical Activity Observed During Dose Escalation
ACR-2316 CLINICAL ACTIVITY OBSERVED DURING DOSE ESCALATION BEST TUMOR SHRINKAGE • Two weekly oral dosing schedules established • Clinical activity observed at ≥120 mg (80% disease control rate; tumor shrinkage in 9/20 evaluable patients), including in SCLC and sqNSCLC, tumor types not typically sens
Acrivon Therapeutics — TD Cowen Healthcare Conference 2026 on 6ix